Skip to main content
. Author manuscript; available in PMC: 2021 Sep 3.
Published in final edited form as: Mol Cell. 2020 Jul 14;79(5):812–823.e4. doi: 10.1016/j.molcel.2020.06.031

Figure 2. NTD and LBD annotation validation by antibody labeling.

Figure 2.

(A) AR-Ab1 labels the NTDs. Top panel, schematic representation of AR functional domains. The long yellow bar represents the region (residues 98–503) recognized by the AR-Ab1. The vertical red bar represents the FXXLF motif (residue 23–27). Bottom panel, AR-Ab1 (yellow) binding to the NTD-a and -b in segmented ARE-DNA/AR density. The stronger antibody density is labeled as AR-Ab1 (Ⅰ) and the other one is labeled as AR-Ab1 (Ⅱ). (B) AR-Ab2 labels the NTD and the interface between the NTD and LBD. Top panel, AR-Ab2 recognizes the residues 39–97 (horizontal yellow bar) at the N-terminal end of AR, which is adjacent to the FXXLF, a motif mediating the interaction between NTD and LBD. Bottom panel, the AR-Ab2 (yellow) binding to the NTD-b in segmented ARE-DNA/AR density. It is located close to the interface between NTD-b and LBD-b, consistent with the segmentation result. See also Supplemental Figure 2.